HER-2/neu intracellular domain protein

BIOLOGICAL4 trials

Sponsors

Duke University, University of Washington

Conditions

Breast CancerGastric CancerHER2-positive Breast CancerHER2/Neu PositiveMale Breast CancerOvarian CancerRecurrent Breast CarcinomaStage IIIB Breast Cancer

Phase 1

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

CompletedNCT01922921

University of WashingtonHER2/Neu Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer

Start: 2014-02-05End: 2021-09-01Updated: 2023-04-18

Phase 2

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

CompletedNCT00343109

University of WashingtonHER2-positive Breast Cancer, Male Breast Cancer, Stage IIIB Breast Cancer +2

Start: 2004-03-31Updated: 2020-02-12

Unknown Phase

Biological Therapy in Treating Patients With Advanced Cancer

CompletedNCT00005956

Duke UniversityBreast Cancer, Gastric Cancer, Ovarian Cancer

Start: 2000-02-29End: 2002-07-31Updated: 2014-07-09

Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

CompletedNCT00363012

University of WashingtonBreast Cancer

Start: 2006-04-30End: 2010-03-31Updated: 2017-04-05

Related Papers

Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers.

2013-05-1419 citations

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.

2007-09-0637 citations